The role of catecholamines in producing arrhythmias

Pheochromocytoma/paraganglioma-associated cardiomyopathy

Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the sympathetic ganglia (10%). PPGL-associated cardiomyopathies can be chronic or acute, with takotsubo cardiomyopathy being the most often reported. These two types of PPGL-induced cardiomyopathy seem to have different pathophysiological backgrounds. Acute catecholaminergic stress inundates myocardial β-adrenoceptors and leads to left ventricle stunning and slight histological apoptosis. In chronic cardiomyopathy, prolonged catecholamine exposure leads to extended myocardial fibrosis, inflammation, and necrosis, and ultimately it causes dilated cardiomyopathy with a low ejection fraction. Sometimes, especially in cases associated with hypertension, hypertrophic cardiomyopathy can develop. The prognosis appears to be worse in chronic cases with a higher hospital mortality rate, higher cardiogenic shock rate at initial presentation, and lower left ventricular recovery rate after surgery. Therefore, establishing the correct diagnosis at an early stage of a PPGL is essential. This mini-review summarizes current data on pathophysiological pathways of cardiac damage caused by catecholamines, the clinical presentation of PPGL-induced cardiomyopathies, and discusses treatment options.

Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week

Pheochromocytomas, arising from chromaffin cells, produce catecholamines, epinephrine and norepinephrine. The tumor biochemical phenotype is defined by which of these exerts the greatest influence on the cardiovascular system when released into circulation in high amounts. Action on the heart and vasculature can cause potentially lethal arrhythmias, often in the setting of comorbid blood pressure derangements. In a review of electrocardiograms obtained on pheochromocytoma patients (n = 650) treated at our institution over the last decade, severe and refractory sinus tachycardia, atrial fibrillation, and ventricular tachycardia were found to be the most common or life-threatening catecholamine-induced tachyarrhythmias. These arrhythmias, arising from catecholamine excess rather than from a primary electrophysiologic substrate, require special considerations for treatment and complication avoidance. Understanding the synthesis and release of catecholamines, the adrenoceptors catecholamines bind to, and the cardiac and vascular response to epinephrine and norepinephrine underlies optimal management in catecholamine-induced tachyarrhythmias.

Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci

Meta-analyses of association results for blood pressure using exome-centric single-variant and gene-based tests identified 31 new loci in a discovery stage among 146,562 individuals, with follow-up and meta-analysis in 180,726 additional individuals (total n = 327,288). These blood pressure-associated loci are enriched for known variants for cardiometabolic traits. Associations were also observed for the aggregation of rare and low-frequency missense variants in three genes, NPR1, DBH, and PTPMT1. In addition, blood pressure associations at 39 previously reported loci were confirmed. The identified variants implicate biological pathways related to cardiometabolic traits, vascular function, and development. Several new variants are inferred to have roles in transcription or as hubs in protein-protein interaction networks. Genetic risk scores constructed from the identified variants were strongly associated with coronary disease and myocardial infarction. This large collection of blood pressure-associated loci suggests new therapeutic strategies for hypertension, emphasizing a link with cardiometabolic risk.

[Association of sleep-disordered breathing and malignant arrhythmias in patients with ischemic and dilated cardiomyopathy]

Sleep-disordered breathing (SDB) has so far been a neglected comorbidity in patients with cardiac arrhythmias. Recently however, several studies have revealed a correlation between SDB and malignant ventricular arrhythmias. This review article is intended to provide the reader with an update on the pathophysiological association between SDB and ventricular arrhythmias, available clinical data, and therapeutic options.

Magnesium therapy in massive digoxin intoxication

A potentially fatal case of massive digitalis intoxication is presented. Recurrent ventricular fibrillation failed to respond to lidocaine or phenytoin, but responded dramatically to magnesium sulfate infusion. A review of the literature and previous clinical studies, as well as the case reported here, appears to indicate that magnesium sulfate given intravenously in adequate quantities (2 to 3 g in one minute followed by 2 g/h for 4 to 5 h) is effective in controlling ventricular irritability caused by toxic levels of digitalis preparations.

Ventricular premature contractions: a randomized non-drug intervention trial in normal men

The influence of a 6-week intervention on factors thought to be related to ectopic cardiac rhythms was tested in normal men with frequent ventricular premature contractions (VPCs), using a randomized, controlled and partial crossover design. The VPC intervention trial experimental regimen included total abstinence from caffeine and smoking, reduction of alcohol intake, and a physical conditioning program. Effects were studied in detail among 81 healthy men with persistent VPCs. VPCs were measured during standard states of rest, dynamic and isometric exercise and other stresses, and 24-hour ambulatory monitoring. Adherence to the treatment was excellent. The experimental group achieved more than 80% of activities asked of them, and little "contamination" occurred in the control group. VPCs were analyzed according to VPC/min, VPC/man and VPC/total number of heart beats. Moderate changes in VPC rates occurred in both experimental and control groups but no significant group differences were found at rest or during any induction test. This 6-week, multiple-factor "hygienic" intervention program had no significant influence on the frequency or occurrence of VPCs in apparently normal men with persistent and frequent VPCs. Because the mechanisms and the significance of VPCs are different in patients with ischemic heart disease, our approach and methods may be useful for similar trials among cardiac patients of adjunct or non-drug therapy for ectopic rhythms.

Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics

The new 5HT-uptake inhibitor, FG 4963, and some tricyclic thymoleptics antagonized p-chloroamphetamine (PCA)-induced hypermotility in rats. FG 4963 was active in about the same s.c. and p.o. doses as chlorimipramine. FG 4963, imipramine and chlorimipramine potentiated hypermotility induced in mice by the 5HT precursor 5HTP, FG 4963 being slighly more active than chlorimipramine. In contrast to the tricyclic thymoleptics FG 4963 did not potentiate the heart rate increasing effect of NA in pithed rats. The peripheral anticholinergic effect of FG 4963 and of desipramine was almost identical while the other imipramine derivatives were more active. All tricyclic thymoleptics were strong peripheral antihistaminics, but FG 4963 was almost devoid of this action. Acute tests for ECG changes in guinea pigs and toxicity in mice and rats showed that FG 4963 and chlorimipramine were less toxic than imipramine and amitriptyline. FG 4963 is presumably a selective 5HT-uptake inhibitor producing much less potentiation of peripheral sympathetic mechanisms than do the tricyclic antidepressants.

Neurochemical and pharmacological studies on a new 5HT-uptake inhibitor, FG4963, with potential antidepressant properties

A new phenylpiperidine derivative, FG4963, and several tricyclic antidepressants were compared in various in vitro and in vivo tests for central 5HT- and NA-uptake inhibition. FG4963 was found to be a 5HT-pump blocker with activity similar to that of chlorimipramine. FG4963 inhibited NA-uptake less than the most potent tricyclic thymoleptics. In contrast to imipramine derivatives FG4963 was a weak inhibitor of peripheral NA-uptake. FG4963 seems to produce central 5HT-potentiation without affecting organ functions regulated by the autonomic nervous system as much as tricyclic antidepressants.

Myocardial damage and cardiac arrhythmias after intracranial hemorrhage. A critical review

Evidence is presented which supports the theory that intracranial hemorrhage may secondarily cause myocardial damage and cardiac arrhythmias.

Fatal intracranial hemorrhage occasionally is accompanied by ECG changes which are consistent with myocardial infarction; histological examination of the heart revealed a variable amount of myocardial damage. After intracranial hemorrhage in animals, myocardial damage was frequent. Similar myocardial damage was produced in animals by intravenous infusion of norepinephrine or acetylcholine and by electrical stimulation of the stellate ganglia, vagus nerve or mesencephalic reticular formation.

Atrial and ventricular arrhythmias and various degrees of A-V block were reported in patients suffering from subarachnoid hemorrhage. Similar cardiac arrhythmias were found in animals after intracranial hemorrhage, and with electrical stimulation of the vagus nerve, stellate ganglia or CNS centers. Available data suggest that increased or altered autonomic activity may be the mechanism whereby intracranial hemorrhage produces myocardial damage and cardiac arrhythmias.

The efficacy of autonomic blockade in preventing myocardial damage, which was secondary to experimental intracranial hemorrhage in animals, was demonstrated. It is suggested that the initiation of therapy with autonomic blocking drugs, as soon as possible after the onset of intracranial hemorrhage in patients, may be useful in preventing myocardial damage and cardiac arrhythmias.

Role of the vagus nerves in the cardiovascular changes induced by coronary occlusion

The importance of vagus nerves to the heart rate, contractile force, blood pressure, and incidence of fatal arrhythmias produced by occlusion of the anterior descending branch of the left coronary artery was studied in chloralose-anesthetized cats. Occlusion performed in 20 animals with intact vagus nerves produced significant decreases in heart rate (23 ± 5.3 beats/min), contractile force (23 ± 6.6%), and blood pressure (20 ± 2.7 mm Hg). Time to onset of arrhythmias was 2.6 ± 0.4 minutes and death due to ventricular fibrillation occurred in four of 20 animals. Occlusion performed in 20 animals with bilateral vagotomy and 20 animals with intact vagus nerves but pretreated with atropine did not decrease heart rate and resulted in significantly more deaths. Time to onset of the arrhythmia was significantly less in both cases. Occlusion produced the usual decrease in contractile force and blood pressure. In addition, a delayed (i.e., after sinus rhythm was restored) decrease in blood pressure and contractile force occurred in animals with vagus nerves sectioned. Pacing hearts of animals with intact and functional vagus nerves to rates comparable to those seen in vagotomized and atropinized cats resulted in a mortality rate identical to that seen in controls. On the other hand, time to onset of the arrhythmia was significantly less than controls and equivalent to the onset times of the vagotomized and atropinized groups. These results suggest that 1) efferent vagus nerves mediate sinus bradyeardia that occurs after coronary occlusion, 2) presence of efferent vagus tone per se reduces the incidence of death, 3) rate effect of efferent vagal tone increases the time to onset of arrhythmias, and 4) presence of afferent vagal tone counteracts the late decline in arterial pressure and contractile force.

Deleterious effects of bretylium in cats with digitalis-induced ventricular tachycardia

The effect of bretylium on ventricular tachycardia induced by digitalis was studied in Dialurethane-anesthetized cats with continuous monitoring of the electrocardiogram and arterial blood pressure. Ventricular tachycardia was produced by repeated injections of deslanoside (25 µg/kg) at 15 min intervals. Only one of eight animals showed conversion of ventricular tachycardia to sinus rhythm with bretylium administration (2-100 mg/kg i.v.). In each animal, bretylium increased the ventricular rate. The effect of bretylium (30 mg/kg i.v.) on duration of ventricular tachycardia induced by deslanoside (0.75 µg/kg/min) was also studied. Duration was shortened from 65 ± 8.0 min to 7 ± 1.0 min, but the reduction was due to the intervention of either ventricular fibrillation or severe hypotension caused by bretylium. Pretreatment with propranolol (0.5 mg/kg i.v.) prevented these deleterious effects and unmasked an antiarrhythmic effect of bretylium since duration of ventricular tachycardia was significantly shorter (40 ± 6.0 min) than the controls (65 ± 8.0 min). In addition, an antiarrhythmic effect of bretylium was noted when it was administered as a dose of 30 mg/kg ip to animals 24 and 4 hours prior to deslanoside intoxication; 231 µg/kg deslanoside were now required for inducing ventricular tachycardia as compared to 175 µg/kg deslanoside in controls. Thus, bretylium given alone during a digitalis-induced ventricular tachycardia increases both the rate of ventricular tachycardia and the likelihood of ventricular fibrillation. These deterious effects appear to be related to a norepinephrine-releasing action and may be avoided by either pretreatment with propranolol or administration of bretylium several hours prior to digitalis intoxication.